− | A '''[[Vaccines|vaccination]]''' is available for control and is widely used. Both '''inactivated and live attenuated''' vaccines are available. The vaccination schedule consists of two vaccinations at a 3-week interval for inactivated vaccines, starting from the age of 3-4 months to avoid interference with colostral antibodies. Live attenuated vaccines are administered either once or twice depending on the type of vaccine. Duration of immunity usually lasts from '''six months to one year'''. Vaccination is recommended for young calves to prevent clinical signs. Vaccination of calves less than 3 months of age can be achieved by intranasal administration of attenuated vaccine. This route is better for overcoming interference due to maternal immunity. Vaccinations should '''protect cattle clinically''' in case of infection and significantly '''reduce the shedding''' of field virus. '''Marker vaccines''' are also available and recommended. | + | A '''[[Vaccines|vaccination]]''' is available for control and is widely used. Both '''inactivated and live attenuated''' vaccines are available. The vaccination schedule consists of two vaccinations at a 3-week interval for inactivated vaccines, starting from the age of 3-4 months to avoid interference with colostral antibodies. Live attenuated vaccines are administered either once or twice depending on the type of vaccine. Duration of immunity usually lasts from '''six months to one year'''. Vaccination is recommended for young calves to prevent clinical signs. Vaccination of calves less than 3 months of age can be achieved by intranasal administration of attenuated vaccine. This route is better for overcoming interference due to maternal immunity. Vaccinations should '''protect cattle clinically''' in case of infection and significantly '''reduce the shedding''' of field virus. Vaccinating latently infected animals may reduce the level of shedding from this group. '''Marker vaccines''' are also available and recommended. These are based on glycoprotein E (gE) deleted mutants, with detectable antibodies present to the gE antigen in marker vaccinated individuals indicating wild-type viral infection. |